Back to Projects

Prevention of breast cancer by Denosumab in women carrying a BRCA1 or BRCA2 mutation (“BRCA-P trial”)

Christian Singer, M.D., M.P.H.
Professor, University of Vienna, Vienna, Austria
Medical University of Vienna

Dr. Singer was awarded funds to lead the ABCSG (Austrian Breast Cancer Study Group) at the Medical University of Vienna to support the collaborative working group meetings of the BRCA-P [denosumab prevention] Steering Committee as well as preparatory work related to the creation of the study’s protocol.

The ABCSG group has hypothesized that denosumab, used to treat osteoporosis or breast cancer spread to bone, may be ‘repurposed’ as a prevention drug. BRCA-P is an international randomized controlled trial that will determine if denosumab prevents breast cancer. The protocol was approved and the trial, BRCA-P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers, began enrolling patients in 2018.

One Arts Plaza
1722 Routh Street | Suite 770
Dallas, Texas 75201
Phone: 1-844-437-4891
Donate at Southwestern Medical Foundation/CPI
CPI is a 501(c)(3) organization 47-3425850 



David Taylor Digital | Digital Marketing Agency